Discussion
TNBC, HER2-positive, tumor
PROLIFERATION, TUMOR GROWTH, TUMOR
We tested, in a cohort of 17 patients affected by early-stage TNBC treated with 3 weeks of olaparib in a “window of opportunity” trial, a mass transfer PDEs-based reactive–diffusive mathematical model of tumor growth which might be capable of efficiently predicting the response to olaparib in terms of SUVThe model showed, without any preliminary assumption, the effective pharmacodynamic efficiency of olaparib was strongly dependent on basal TILs level and SUVThe need for biomarkers to guide escalated/de-escalated and more personalized therapeutic approaches is a hot topic in current OncologyNoteworthy, the evaluation of Ki67 is an already established prognostic biomarker in BC, which expression is strongly associated to tumor proliferation and growthThe morphological evaluation of TILs in BC has gained attention in the last few years, when preliminary evidences started to show a potential prognostic and predictive role, especially in TNBC and HER2-positive BCThere are several limitations that will have to be overcome to promote the implementation of this mathematical framework in the clinical research and practice scenarios. First of all, we had the possibility to study our mathematical model in a cohort of 17 patients, which is more than what is usually done in this research field, where modelling frameworks based on single patients are the normAnother limitation, is that SUVTo conclude, we observed that a mathematical framework based on realistic multidimensional governing PDEs, could be directly applied to the tailored simulation of an early therapeutic response to the PARPi olaparib in early-stage TNBC by using Prospective evaluation in independent cohorts and correlation of these outcomes with more recognized efficacy endpoints is now warranted.